PMID- 33854752
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220422
IS  - 2042-0188 (Print)
IS  - 2042-0196 (Electronic)
IS  - 2042-0188 (Linking)
VI  - 12
DP  - 2021
TI  - Increased serum calcium levels are associated with carotid atherosclerotic plaque 
      in normocalcaemic individuals with type 2 diabetes.
PG  - 2042018821995369
LID - 10.1177/2042018821995369 [doi]
LID - 2042018821995369
AB  - BACKGROUND: Patients with type 2 diabetes mellitus (T2DM) have an elevated risk 
      of atherosclerotic cardiovascular disease. Although previous data have suggested 
      that serum calcium levels could be involved in T2DM and cardiovascular disease, 
      whether this applies in T2DM patients with atherosclerosis remains unclear. This 
      study therefore aimed to investigate the relationship between serum calcium 
      levels within the physiological ranges and carotid atherosclerotic plaque in T2DM 
      patients. METHODS: A total of 594 normocalcaemic in-patients with T2DM were 
      recruited, of whom 231 had carotid atherosclerotic plaque. Serum calcium levels 
      were measured and carotid ultrasonography was performed. RESULTS: Patients with 
      plaque had significantly higher serum albumin-corrected calcium than those 
      without plaque [9.02 (8.78-9.34) mg/dL versus 8.86 (8.66-9.06) mg/dL, p < 0.001]. 
      As serum albumin-corrected calcium levels increased across tertiles, the 
      percentage of plaque increased (27.6%, 35.5%, and 55.7%; p < 0.001). Logistic 
      regression showed that serum albumin-corrected calcium levels were independently 
      and positively correlated with the presence of plaque, but not parathyroid 
      hormone levels. Compared with patients in the lowest serum calcium tertiles, the 
      odds ratio for plaque in patients in the upper quartile was 2.47 (95% confidence 
      interval 1.51-4.03, p < 0.001) after adjustment for potential confounders. 
      CONCLUSION: Serum albumin-corrected calcium levels are elevated in patients with 
      T2DM and carotid atherosclerotic plaques.
CI  - (c) The Author(s), 2021.
FAU - Zhu, Huijing
AU  - Zhu H
AD  - Department of Endocrinology and Metabolism, The First Affiliated Hospital of 
      Soochow University, Suzhou, Jiangsu, China.
FAU - Wang, Huili
AU  - Wang H
AD  - Department of Endocrinology & Metabolism, Heze Municipal Hospital, Heze, 
      Shandong, China.
FAU - Jia, Yuqing
AU  - Jia Y
AD  - Department of Cardiology, Heze Municipal Hospital, 2888 Caozhou Road, Heze, 
      Shandong, 274031, China.
FAU - Cheng, Lin
AU  - Cheng L
AD  - Department of Endocrinology & Metabolism, Heze Municipal Hospital, Heze, 
      Shandong, China.
FAU - Cheng, Xingbo
AU  - Cheng X
AUID- ORCID: 0000-0001-8697-4655
AD  - Department of Endocrinology and Metabolism, The First Affiliated Hospital of 
      Soochow University, 188 Shizi Road, Suzhou, Jiangsu 215006, China.
LA  - eng
PT  - Journal Article
DEP - 20210329
PL  - United States
TA  - Ther Adv Endocrinol Metab
JT  - Therapeutic advances in endocrinology and metabolism
JID - 101532143
PMC - PMC8010831
OTO - NOTNLM
OT  - atherosclerosis
OT  - calcium
OT  - carotid plaques
OT  - type 2 diabetes
COIS- Conflict of interest statement: The authors declare that there is no conflict of 
      interest.
EDAT- 2021/04/16 06:00
MHDA- 2021/04/16 06:01
PMCR- 2021/03/29
CRDT- 2021/04/15 07:20
PHST- 2020/07/30 00:00 [received]
PHST- 2021/01/22 00:00 [accepted]
PHST- 2021/04/15 07:20 [entrez]
PHST- 2021/04/16 06:00 [pubmed]
PHST- 2021/04/16 06:01 [medline]
PHST- 2021/03/29 00:00 [pmc-release]
AID - 10.1177_2042018821995369 [pii]
AID - 10.1177/2042018821995369 [doi]
PST - epublish
SO  - Ther Adv Endocrinol Metab. 2021 Mar 29;12:2042018821995369. doi: 
      10.1177/2042018821995369. eCollection 2021.